# Oxford Immunotec Global PLC (OXFD)

Source: https://www.quantisnow.com/company/OXFD
Generated: 2026-11-09T16:45:24.819Z

- Ticker: OXFD
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: In Vitro & In Vivo Diagnostic Substances
- IPO year: 2013

## Latest OXFD news and filings

- 2021-05-07 21:05 UTC [SEC Schedule 13G] [SEC Form SC 13G filed by Oxford Immunotec Global PLC](https://www.quantisnow.com/insight/sec-form-sc-13g-filed-by-oxford-immunotec-global-plc-718436)
- 2021-03-18 20:35 UTC [SEC Form 15-12B] [SEC Form 15-12B filed by Oxford Immunotec Global PLC](https://www.quantisnow.com/insight/sec-form-15-12b-filed-by-oxford-immunotec-global-plc-528608)
- 2021-03-12 21:38 UTC [SEC Form S-8 POS filed](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-507221)
- 2021-03-12 21:37 UTC [SEC Form 4] [SEC Form 4: Herm Rosenman disposed to the issuer $89,782 worth of Ordinary Shares (4,081 units at $22.00), decreasing direct ownership by 100% to 0 units](https://www.quantisnow.com/insight/sec-form-4-herm-rosenman-disposed-to-the-issuer-89782-507213)
- 2021-03-12 21:37 UTC [SEC Form 4] [SEC Form 4: E T Matthew Mclaughlin disposed to the issuer $1,350,954 worth of Ordinary Shares (61,407 units at $22.00), decreasing direct ownership by 100% to 0 units](https://www.quantisnow.com/insight/sec-form-4-e-t-matthew-mclaughlin-disposed-to-the-507207)
- 2021-03-12 21:36 UTC [SEC Form 4] [SEC Form 4: A Richard Sandberg disposed to the issuer $89,782 worth of Ordinary Shares (4,081 units at $22.00), decreasing direct ownership by 100% to 0 units](https://www.quantisnow.com/insight/sec-form-4-a-richard-sandberg-disposed-to-the-issuer-507203)
- 2021-03-12 21:36 UTC [SEC Form 4] [SEC Form 4: R. Mark Klausner disposed to the issuer $89,782 worth of Ordinary Shares (4,081 units at $22.00), decreasing direct ownership by 100% to 0 units](https://www.quantisnow.com/insight/sec-form-4-r-mark-klausner-disposed-to-the-issuer-507197)
- 2021-03-12 21:36 UTC [SEC Form 4] [SEC Form 4: Patricia Randall disposed to the issuer $611,710 worth of Ordinary Shares (27,805 units at $22.00), decreasing direct ownership by 100% to 0 units](https://www.quantisnow.com/insight/sec-form-4-patricia-randall-disposed-to-the-issuer-611710-507194)
- 2021-03-12 21:36 UTC [SEC Form 4] [SEC Form 4: Louise Janet Kidd disposed to the issuer $246,554 worth of Ordinary Shares (11,207 units at $22.00), decreasing direct ownership by 100% to 0 units](https://www.quantisnow.com/insight/sec-form-4-louise-janet-kidd-disposed-to-the-issuer-507193)
- 2021-03-12 21:36 UTC [SEC Form 4] [SEC Form 4: J Patrick Balthrop disposed to the issuer $177,782 worth of Ordinary Shares (8,081 units at $22.00), decreasing direct ownership by 100% to 0 units](https://www.quantisnow.com/insight/sec-form-4-j-patrick-balthrop-disposed-to-the-issuer-507188)
- 2021-03-12 21:35 UTC [SEC Form 4] [SEC Form 4: Scott Andrew Walton disposed to the issuer $89,782 worth of Ordinary Shares (4,081 units at $22.00), decreasing direct ownership by 100% to 0 units](https://www.quantisnow.com/insight/sec-form-4-scott-andrew-walton-disposed-to-the-issuer-507185)
- 2021-03-12 21:35 UTC [SEC Form 4] [SEC Form 4: Peter Wrighton-Smith disposed to the issuer $8,804,950 worth of Ordinary Shares (400,225 units at $22.00), decreasing direct ownership by 100% to 0 units](https://www.quantisnow.com/insight/sec-form-4-peter-wrighton-smith-disposed-to-the-issuer-8804950-507183)
- 2021-03-12 21:35 UTC [SEC Form 4] [SEC Form 4: Asbury Ronald Andrews disposed to the issuer $89,782 worth of Ordinary Shares (4,081 units at $22.00), decreasing direct ownership by 100% to 0 units](https://www.quantisnow.com/insight/sec-form-4-asbury-ronald-andrews-disposed-to-the-issuer-507178)
- 2021-03-12 21:35 UTC [SEC Form S-8 POS filed](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-507176)
- 2021-03-12 21:35 UTC [SEC Form 4] [SEC Form 4: R James Tobin disposed to the issuer $89,782 worth of Ordinary Shares (4,081 units at $22.00), decreasing direct ownership by 100% to 0 units](https://www.quantisnow.com/insight/sec-form-4-r-james-tobin-disposed-to-the-issuer-507175)
- 2021-03-08 22:05 UTC [SEC Schedule 13G] [SEC Form SC 13G filed](https://www.quantisnow.com/insight/sec-form-sc-13g-filed-485221)
- 2021-03-08 21:35 UTC [SEC Form 8-K filed](https://www.quantisnow.com/insight/sec-form-8-k-filed-484902)
- 2021-03-08 14:24 UTC [SEC Form 25-NSE filed](https://www.quantisnow.com/insight/sec-form-25-nse-filed-483076)
- 2021-03-04 19:26 UTC [Oxford Immunotec Submits Emergency Use Authorization Request to the FDA and CE Marks T-SPOT®.COVID, a Test for the Detection of a Cell Mediated (T cell) Immune Response to SARS-CoV-2 Infection](https://www.quantisnow.com/insight/oxford-immunotec-submits-emergency-use-authorization-request-to-the-fda-473960)
- 2021-03-02 22:00 UTC [SEC Form 8-K/A filed](https://www.quantisnow.com/insight/sec-form-8-ka-filed-461528)
- 2021-02-26 22:17 UTC [SEC Form 8-K filed](https://www.quantisnow.com/insight/sec-form-8-k-filed-448145)
- 2021-02-17 20:14 UTC [SEC Schedule 13G] [SEC Form SC 13G/A filed](https://www.quantisnow.com/insight/sec-form-sc-13ga-filed-405474)
- 2021-02-16 21:19 UTC [SEC Schedule 13G] [SEC Form SC 13G/A filed](https://www.quantisnow.com/insight/sec-form-sc-13ga-filed-402184)
- 2021-02-16 19:39 UTC [SEC Schedule 13G] [SEC Form SC 13G/A filed](https://www.quantisnow.com/insight/sec-form-sc-13ga-filed-400774)
- 2021-02-16 16:21 UTC [SEC Schedule 13G] [SEC Form SC 13G filed](https://www.quantisnow.com/insight/sec-form-sc-13g-filed-399056)
- 2021-02-16 12:32 UTC [SEC Schedule 13G] [SEC Form SC 13G/A filed](https://www.quantisnow.com/insight/sec-form-sc-13ga-filed-396433)
- 2021-02-12 21:05 UTC [SEC Schedule 13G] [SEC Form SC 13G/A filed](https://www.quantisnow.com/insight/sec-form-sc-13ga-filed-390775)
- 2021-02-12 20:41 UTC [SEC Schedule 13G] [SEC Form SC 13G filed](https://www.quantisnow.com/insight/sec-form-sc-13g-filed-390455)
- 2021-02-11 21:43 UTC [SEC Schedule 13G] [SEC Form SC 13G/A filed](https://www.quantisnow.com/insight/sec-form-sc-13ga-filed-385458)
- 2021-02-11 01:35 UTC [SEC Schedule 13G] [SEC Form SC 13G filed](https://www.quantisnow.com/insight/sec-form-sc-13g-filed-380507)
- 2021-02-10 21:35 UTC [SEC Schedule 13G] [SEC Form SC 13G/A filed](https://www.quantisnow.com/insight/sec-form-sc-13ga-filed-378889)
- 2021-02-08 14:15 UTC [Oxford Immunotec Enters a Memorandum of Understanding (MOU) with GC MS (Green Cross Medical Science Corp. – South Korea) to Market the T-SPOT® Discovery SARS-CoV-2 Kit, for the Measurement of the T Cell Immune Response to SARS-CoV-2 Infection, in South Korea](https://www.quantisnow.com/insight/oxford-immunotec-enters-a-memorandum-of-understanding-mou-with-gc-362120)
- 2021-02-04 14:15 UTC [Oxford Immunotec Updates Their T-SPOT® Discovery SARS-CoV-2 Kit and Include a New Panel to Detect T Cells Reactive to Endemic Coronaviruses](https://www.quantisnow.com/insight/oxford-immunotec-updates-their-t-spot-discovery-sars-cov-2-kit-and-include-352774)
- 2021-02-03 21:27 UTC [SEC Schedule 13G] [SEC Form SC 13G filed](https://www.quantisnow.com/insight/sec-form-sc-13g-filed-348919)
- 2021-01-29 14:54 UTC [SEC Form SC 13D filed](https://www.quantisnow.com/insight/sec-form-sc-13d-filed-329478)
- 2021-01-29 14:27 UTC [SEC Form DEFM14A filed](https://www.quantisnow.com/insight/sec-form-defm14a-filed-329310)
- 2021-01-19 22:23 UTC [SEC Form PREM14A filed](https://www.quantisnow.com/insight/sec-form-prem14a-filed-295947)
- 2021-01-14 14:15 UTC [New Monthly Series Spotlights What 100 Physicians Find to be Critical Needs in Their Battle Against COVID-19](https://www.quantisnow.com/insight/new-monthly-series-spotlights-what-100-physicians-find-to-be-284647)
- 2021-01-13 14:15 UTC [Oxford Immunotec’s T-SPOT® Discovery SARS-CoV-2 Test is Used to Measure the Efficacy of Valneva’s VLA2001 COVID-19 Vaccine Candidate in a Phase I/II Clinical Study](https://www.quantisnow.com/insight/oxford-immunotecs-t-spot-discovery-sars-cov-2-test-is-used-to-measure-281022)
- 2021-01-08 22:19 UTC [SEC Form SC 13G/A filed](https://www.quantisnow.com/insight/sec-form-sc-13ga-filed-270177)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/OXFD
- Earnings history: https://www.quantisnow.com/earnings/OXFD
- Dividend history: https://www.quantisnow.com/dividends/OXFD
- Insider transactions: https://www.quantisnow.com/insiders/OXFD
- Options chain: https://www.quantisnow.com/options/OXFD
- SEC 8-K filings only: https://www.quantisnow.com/company/OXFD/8-k
- RSS and alerts for OXFD: https://www.quantisnow.com/docs/rss-feeds.md